EUCTR2007-002586-12-DE进行中（未招募）不适用
Twice-daily oral direct thrombin inhibitor dabigatran in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. - Re-Sonate
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients with confirmed symptomatic PE or proximal DVT of the legs who have been treated for 6 to 18 months* with therapeutic dosages (intended INR between 2 - 3) of an oral VKA (e.g., warfarin, acenocoumarol, phenprocoumon, or fluindione) or RE-COVER study medication up to the moment for the current study.
- •*bridging therapy for any reason within the 6 - 18 months of VKA therapy is allowed for a maximum of 30 days
- •2. Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Younger then 18 years of age
- •2. Indication for VKA other than DVT and/or PE
- •3. Patients in whom anticoagulant treatment for their index PE or DVT should be
- •4. Active liver disease or liver disease decreasing survival (e.g. acute hepatitis,
- •chronic active hepatitis, cirrhosis) or ALAT > 3 x ULN
- •5. Creatinine clearance < 30 ml/min
- •6. Acute bacterial endocarditis
- •7. Patients who in the investigator’s judgement are perceived as having an excessive risk of bleeding, for example because of anticipated need of quinidine or other restricted medication during the treatment period
- •8. Uncontrolled hypertension (investigators judgement)
- •9. Intake of another experimental drug within the 30 days prior to randomization
- •into the study with the exception of patients participating in RE-COVER (BI study 1160.53)
- •10. Life expectancy < 6months
- •11. Childbearing potential without proper contraceptive measures*, pregnancy or
- •breast feeding
- •*proper contraceptive measures are defined as a method of contraception with a failure rate < 1 % during the course of the study (including the observational period). These methods of contraception according to the note for guidance on non-clinical safety studies for the conduct of human trials for pharmaceuticals (CPMP/ICH/286/95, modification) include consistent and correct use of hormone containing implants and injectables, combined oral contraceptives, hormone containing intrauterine devices, surgical sterilization, sexual abstinence and vasectomy
- •12. Patients with known hypersensitivity to dabigatran or any other component of the
- •investigational product
- •13. Patients deemed unsuitable for inclusion by the investigator, because
- •considered unreliable to comply with the requirements of the study and/or
- •compliance with study drug administration, or because having any condition or
- •disease which in the opinion of the investigator would not allow safe
- •participation in the study
- •14. Patients with known active cancer
- •15. Patients with a contraindication to systemic anticoagulation
研究者
相似试验
进行中（未招募）
不适用
Twice-daily oral direct thrombin inhibitor dabigatran in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. - Re-Sonatelong-term prevention of recurrent symptomatic venous thromboembolism (VTE) in patients with symptomatic deep-vein thrombosis (DVT) or pulmonary embolism (PE) who completed 6 to 18 months of treatment with a vitamin K antagonist (VKA).MedDRA version: 9.1Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisEUCTR2007-002586-12-CZBoehringer Ingelheim Pharma GesmbH1,800
进行中（未招募）
不适用
Twice-daily oral direct thrombin inhibitor dabigatran in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. - Re-Sonatelong-term prevention of recurrent symptomatic venous thromboembolism (VTE) in patients with symptomatic deep-vein thrombosis (DVT) or pulmonary embolism (PE) who completed 6 to 18 months of treatment with a vitamin K antagonist (VKA).MedDRA version: 9.1Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisEUCTR2007-002586-12-EEBoehringer Ingelheim RCV GmbH & Co KG1,800
进行中（未招募）
不适用
Twice-daily oral direct thrombin inhibitor dabigatran in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. - Re-Sonatelong-term prevention of recurrent symptomatic venous thromboembolism (VTE) in patients with symptomatic deep-vein thrombosis (DVT) or pulmonary embolism (PE) who completed 6 to 18 months of treatment with a vitamin K antagonist (VKA).MedDRA version: 9.1Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisEUCTR2007-002586-12-SEBoehringer Ingelheim AB1,800
进行中（未招募）
不适用
Twice-daily oral direct thrombin inhibitor dabigatran in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. - Re-SonateEUCTR2007-002586-12-PLBoehringer Ingelheim Pharma GesmbH1,800
进行中（未招募）
1 期
Twice-daily oral direct thrombin inhibitor dabigatran in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. - Re-SonateEUCTR2007-002586-12-BESCS Boehringer Ingelheim Comm.V1,800